Category Archives: pricing

PPRS Payments Now Worth £150m in the UK

By Leela Barham. A second payment has now been made under the UK’s Pharmaceutical Price Regulation Scheme (PPRS). Adding a further £76m to the £74m for the first quarter of 2014, the payments received by the Department of Health (DH) now total £150m (US$244m).  Payments are a new feature of the long-standing voluntary PPRS. The […]
Also posted in Europe, Guest Blog, Op-Ed, Regulatory | Tagged , , | Leave a comment

Managing High-Priced, US Biotech Rxs in Canada

As the “Saga of Sovaldi” continues to unfold in the U.S., and Congress, insurers, providers, and the U.S. Rx manufacturer, Gilead, hurl charges back and forth at each other, it’s pretty clear the situation will only continue to deteriorate. However, as you look north of the American border, it’s striking how Canadian healthcare entities are managing […]
Also posted in Op-Ed | Tagged , , , , | Leave a comment

UK’s Controversial Cancer Fund Boosted — But What’s the Long-Term Plan?

By Leela Barham. The English Cancer Drugs Fund (CDF), set up to provide funding for those products that the National Institute for Health and Care Excellence (NICE) has not recommended for use or where their guidance isn’t yet available, remains controversial. Initially penciled for closure in 2014, it is now planned to run to 2016. […]
Also posted in Europe, Guest Blog, Op-Ed | Tagged , , , , , , | Leave a comment

Europe: More Direct-Acting Antivirals, More Controversy

The storms raging across Europe—and beyond—over the pricing of new hepatitis C treatments have been intensified by the European Union’s approval last week of the latest directly-acting antiviral, Bristol-Myers Squibb’s Daklinza (daclatasvir). Just two months after the European Medicines Agency gave a positive opinion on the drug, the formal authorization was delivered for use in […]
Also posted in Europe, Global, Guest Blog, Op-Ed, Regulatory | Tagged , , , , , , | Leave a comment

Pharmaceutical Care Management Association Releases Hep C Medicare Part D Impact Study

As the controversy over Sovaldi’s $84,000 per therapy cost continues to build, the Pharmaceutical Care Management Association has released a study on the impact of the new Hepatitis C drugs on the overall costs to the US Medicare Part D pharmaceutical program (http://www.pcmanet.org/images/stories/uploads/2014/partdpremiumstudymilliman.pdf)
Also posted in healthcare | Tagged , , , , | Leave a comment
  • Categories

  • Meta